Project description:Comparison between miRNA expression in plasma of women with and without metabolic syndrome. We used microarrays to compare the composition of miRNAs in plasma of participants with and without metabolic syndrome (ATP III criteria).
Project description:Metabolic syndrome is a common and complicated metabolic disorder and defined as a clustering of metabolic risk factors such as insulin resistance or diabetes, obesity, hypertension, and hyperlipidemia. The identification of accurate and effective biomarkers is beneficial to the early diagnosis and treatment of metabolic syndrome. Our study firstly detected the plasma miRNA expression profile of MetS patients compared with control group by high-throughput sequencing and integrated bioinformatics approaches. To our best knowledge, our study firstly perform high-throughput sequencing to obtain the circulating microRNA expression data in MetS plasma, and identified several potential plasma biomarkers for MetS.
Project description:In this work, plasma samples of 5 metabolic syndrome patients and 5 healthy volunteers were collected. Then, high-throughput RNA sequencing was performed to detect the expression of plasma coding RNA.
Project description:Despite a significant progress in the treatment of Acute Respiratory Distress Syndrome (ARDS), our ability to identify early patients and predict outcome remains limited. In this study, we aimed to characterize small RNA content of plasma exosomes from ARDS patients in order to identify potential diagnostic biomarkers of the disease. For the first time, we profiled miRNA expression levels in plasma-derived exosomes from ARDS patients (n=8) compared to healthy subjects (n=10) by small RNA-seq. It allowed us to identify 12 exosomal miRNAs differentially expressed in ARDS context (padj<0.05).
Project description:Breast cancer (BCa) is the leading cause of death by cancer in women worldwide. Early diagnosis is improving the survival of BCa patients but more sensitive and specific tools are still necessary. We propose the use of miRNAs as a biomarker alternative in BCa diagnosis. MiRNAs are small non-coding RNAs that regulate gene expression. Circulating miRNAs can be detected in body fluids. Aberrant expression of miRNAs in both tissues and fluids are linked to several pathologies. Furthermore, metabolic syndrome (MeS) is a risk factor for BCa. Molecular mechanisms underlaying this association have not been fully elucidated. The aim of this work was to identify the circulating miRNAs in plasma of BCa patients and healthy donors with or without clinical features linked to MeS. MiRNAs were isolated from plasma of woman. BCa patients (N=30) were distributed into 5 clusters, according with their BCa stage: i) stages 0 and IA, ii) stage IIA, iii) stage IIB, iv) stage IIIA, and v) stages IIIB, IIIC and IV. Healthy women (HD) (N=36) were recruited and divided in two groups, control or MeS-linked disease (MeSL) when presented two or more of these conditions: BMI≥25.00 kg/m2, waist diameter≥82 cm or high blood pressure (systolic≥120, diastolic≥ 80). We hybridized miRNAs of each group using GeneChip® miRNA 4.0 Array (Affymetrix). miRNA expression profile was also determined by miRNA sequencing from 6 BC patients and 4 HD. Data analysis revealed 11 miRNAs upregulated in the plasma from BCa patients compared to HD. Meanwhile, 24 miRNAs were altered in plasma of women with MeSL compared to control.
Project description:Breast cancer (BCa) is the leading cause of death by cancer in women worldwide. Early diagnosis is improving the survival of BCa patients but more sensitive and specific tools are still necessary. We propose the use of miRNAs as a biomarker alternative in BCa diagnosis. MiRNAs are small non-coding RNAs that regulate gene expression. Circulating miRNAs can be detected in body fluids. Aberrant expression of miRNAs in both tissues and fluids are linked to several pathologies. Furthermore, metabolic syndrome (MeS) is a risk factor for BCa. Molecular mechanisms underlaying this association have not been fully elucidated. The aim of this work was to identify the circulating miRNAs in plasma of BCa patients and healthy donors with or without clinical features linked to MeS. MiRNAs were isolated from plasma of woman. BCa patients (N=30) were distributed into 5 clusters, according with their BCa stage: i) stages 0 and IA, ii) stage IIA, iii) stage IIB, iv) stage IIIA, and v) stages IIIB, IIIC and IV. Healthy women (HD) (N=36) were recruited and divided in two groups, control or MeS-linked disease (MeSL) when presented two or more of these conditions: BMI≥25.00 kg/m2, waist diameter≥82 cm or high blood pressure (systolic≥120, diastolic≥ 80). We hybridized miRNAs of each group using GeneChip® miRNA 4.0 Array (Affymetrix). miRNA expression profile was also determined by miRNA sequencing from 6 BC patients and 4 HD. Data analysis revealed 11 miRNAs upregulated in the plasma from BCa patients compared to HD. Meanwhile, 24 miRNAs were altered in plasma of women with MeSL compared to control.
Project description:Clinical variability in sickle cell disease (SCD) suggests a role for extra-erythrocytic factors in the pathogenesis of vasoocclusion. We hypothesized that one potential factor, endothelial dysfunction, results from induction of phenotypic changes by circulating factors in SCD patients. The database reports gene expression in cultured human pulmonary artery endothelial cells (HPAEC) exposed to plasma from: a) sickle acute chest syndrome (ACS) patients (samples ; b) SCD patients at steady-state and c) normal volunteers using microarrays (U133A-B GeneChip Affymetrix).